Back to Journals » Vascular Health and Risk Management » Volume 4 » Issue 6

The effects of prior calcium channel blocker therapy on creatine kinase-MB levels after percutaneous coronary interventions

Authors Gulmez O, Atar I, Ozin B, Korkmaz ME, Atar A, Aydinalp A, Yildirir A, Muderrisoglu H

Published 5 December 2008 Volume 2008:4(6) Pages 1417—1422

DOI https://doi.org/10.2147/VHRM.S2998

Review by Single anonymous peer review

Peer reviewer comments 3



Oyku Gulmez, Ilyas Atar, Bülent Ozin, Mehmet Emin Korkmaz, Aslı Atar, Alp Aydinalp, Aylin Yildirir, Haldun Muderrisoglu

Baskent University Faculty of Medicine, Department of Cardiology, Ankara, Turkey

Background: Use of intracoronary calcium channel blockers (CCBs) during percutaneous coronary intervention (PCI) has been shown to have favorable effects on coronary blood flow. We aimed to investigate the effects of CCBs administrated perorally on creatine kinase-MB (CK-MB) levels in patients undergoing elective PCI.

Methods: A total of 570 patients who underwent PCI were evaluated for CK-MB elevation. Patients who were on CCB therapy when admitted to the hospital constituted the CCB group. No CCBs were given to the rest of the patients during the periprocedural period and these patients served as the control group. Blood samples for CK-MB were obtained before and at 6 h, 24 h, and 36 h after the procedure.

Results: 217 patients were in the CCB group (mean age 60.2 ± 9.3 years, 162 males), and 353 were in the control group (mean age 60.0 ± 10.1 years, 262 males). CK-MB levels increased above the normal values in 41 patients (18.9%) of the CCBs group and in 97 patients (27.5%) of the control group (p = 0.02). Median CK-MB levels were significantly higher in the control group for all studied hours (for all p < 0.05).

Conclusions: Prior oral CCB therapy may have favorable effects in preventing myocyte necrosis after elective PCI.

Keywords: calcium channel blockers, myonecrosis, percutaneous coronary interventions

Creative Commons License © 2008 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.